American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis

Cited by (359)

Items 201–300 of 359

1. Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019)
   Umesh Kumar Dashora, Dipesh Patel, Robert Gregory, Peter H. Winocour, Ketan Dhatariya, Dinesh Kumar Nagi · 2019 · British Journal of Diabetes
2. Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
   Eiji Kutoh, Teruma Murayama, Asuka Wada, Mitsuru Hirate · 2016 · Drugs in R&D
3. SGLT inhibition in T1DM — definite benefit with manageable risk
   Ele Ferrannini, Anna Solini · 2017 · Nature Reviews Endocrinology
4. Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult
   Brendan J. Nolan, Suresh Varadarajan, Spiros Fourlanos, Sandra L. Neoh · 2020 · The American Journal of Medicine
5. Safety of sodium–glucose c otransporter 2 inhibitors in Asian type 2 diabetes populations
   Jaime A. Davidson, Norlela Sukor, Fen‐Lee Hew, Mafauzy Mohamed, Zanariah Binti Hussein · 2022 · Journal of Diabetes Investigation
6. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes
   Joseph M. Messana, Stanley S. Schwartz, Raymond R. Townsend · 2017 · Vascular Health and Risk Management
7. Euglycemic Diabetic Ketoacidosis Associated With Use of SGLT2 Inhibitor After Laparoscopic Roux-en-Y Gastric Bypass
   Katherine Yared, Gregory J. Mancini · 2020 · The American Surgeon
8. Novel Approach to Continuation of Elective Procedures in People at Risk for Sodium–Glucose Cotransporter 2 Inhibitor–Associated Euglycemic Ketoacidosis
   Matthew Verdone, Jonathan Bauman, Esben Iversen, Rifka Schulman‐Rosenbaum, Anthony C. Antonacci, Sabatino Leffe, Joseph Simpson, Yael Harris, Joseph Marino · 2024 · Diabetes Spectrum
9. Euglycemic Diabetic Ketoacidosis in a Sedated Patient after Coronary Artery Bypass Grafting: A Case Report and Literature Review
   Mohamad S. Alabdaljabar, Khaled Abdullah, Ali S. Almasood, Syed Salman Ali, Abdullah K. Ashmeg · 2021 · Case Reports in Medicine
10. Sodium-Glucose Co-transporter-2 Inhibitors Induced Diabetic Ketoacidosis in Patients Undergoing Bariatric Surgery: a Systematic Review of Case Reports and Case Series
    Nakul Gokhare Viswanath, Mitesh Sharma, Nanda Bandlamudi, ISKANDAR RAUF IDRIS, Rishi Singhal, Kamal Kumar Mahawar, Brijesh Madhok · 2022 · Obesity Surgery
11. An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes
    Georgios Chatzopoulos, Κωνσταντίνος Τζιόμαλος · 2020 · Expert Opinion on Pharmacotherapy
12. Sodium-Glucose Cotransporter 2 Inhibitors in Adult and Pediatric Congenital Heart Disease: Review of Emerging Data and Future Directions
    William H. Marshall V, Lydia Wright · 2024 · Congenital Heart Disease
13. Retrospective Chart Review of Euglycemic Diabetic Ketoacidosis Rates and Outcomes Postimplementation of Sodium Glucose Cotransporter 2 Inhibitor Use Stoppage 5 Days Before Open Heart Surgery
    Jonathan S. Auerbach, Ahmed Alnajar, Samira S. Patel, Hayley Beth Gershengorn, Joseph Lamelas, Daitiara Perez, Oscar Aljure, Tanira Ferreira, Lazaro A. Gonzalez, Jorge Luis Cabrera · 2025 · Journal of Cardiothoracic and Vascular Anesthesia
14. A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition
    Idrisu Sanusi, Alexander Sarnowski, David L Russell-Jones, Lui G. Forni · 2019 · Journal of Critical Care
15. Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
    Beng Leong Lim, Wei Feng Lee, Berlin Lee, Yan Ee Lynette Chung, Kee Vooi Loo · 2023 · BMJ Open
16. Bariatric emergencies for the general surgeon
    Maria S. Altieri, Ann M. Rogers, Cheguevara I. Afaneh, Fady Moustarah, Brandon T. Grover, Zhamak Khorgami, Dan Eisenberg · 2023 · Surgery for Obesity and Related Diseases
17. Euglycemic Diabetic Ketoacidosis Associated With SGLT2 Inhibitor Therapy: A Case Report
    Gwen Klinkner, Maggie Steingraber-Pharr · 2023 · AACN Advanced Critical Care
18. Effect of sodium glucose cotransporter 2 inhibition immediately prior to heart transplantation
    Lisa Mary Raven, Christopher Alan Muir, Ricardo C. Deveza, Cassia Kessler Iglesias, N. Bart, K. Muthiah, Eugene Kotlyar, Chris Hayward, Peter Simon Macdonald, Andrew Jabbour et al. · 2024 · JHLT Open
19. Ketoacidosis related to sodium glucose cotransporter 2 inhibitors after emergency coronary surgery
    Rihito Horikoshi, Tadashi Kitamura, Kagami Miyaji · 2019 · Interactive Cardiovascular and Thoracic Surgery
20. Continuing Professional Development: Diabetes and associated diabetic emergencies
    Ray Higginson, Paul Burrows, Bridie Jones · 2019 · Journal of Paramedic Practice
21. Euglycemic Diabetic Ketoacidosis After Cardiac Surgery in a Patient Treated With Empagliflozin for Type 2 Diabetes Mellitus
    Peter Wohlrab, Matthias Kainz, Arno Schiferer, Bernhard Zapletal, Edda Tschernko · 2021 · Journal of Cardiothoracic and Vascular Anesthesia
22. Perioperative Implication of Sodium-glucose Cotransporter-2 Inhibitor in a Patient Following Major Surgery
    Dheeraj Kapoor, Vidhyadhar Lad · 2021 · Indian Journal of Critical Care Medicine
23. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus
    Rajeev Kumar Jain · 2017 · Expert Opinion on Pharmacotherapy
24. Type 2 diabetes management
    Kajal Gc, Myriam Jean Cadet, Shabeena Hirani, Tisha Thomas · 2018 · The Nurse Practitioner
25. Case of sodium–glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis
    Huei Li Yeoh, Marilyn Lee, Woei Jack Pan, Hean Yee Ong · 2021 · BMJ Case Reports
26. Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: From Metabolic Mechanisms to International Guidelines
    Tamás T. Várkonyi, Krisztina Kupai, Hsu Lin Kang, Danica Matusovits, Dániel Priksz, Ákos Várkonyi, Csaba Lengyel, Anikó Pósa · 2026 · Antioxidants
27. Does Treatment with Sodium‐Glucose Cotransporter‐2 Inhibitors Affect Adherence to International Society Criteria for Diabetic Ketoacidosis in Adult Patients with Type 2 Diabetes? A Retrospective Cohort Analysis
    Aongus O’Brolchain, Joshua Maletsky, Ibrahim Mian, Serena Edwards · 2024 · Journal of Diabetes Research
28. Management of SGLT-2 Inhibitors in the Perioperative Period: Withhold or Continue?
    Zack Pittack · 2025 · British Journal of Hospital Medicine
29. The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial
    Mostafa Najafipour, Farzad Najafipour, Alireza Ostadrahimi, Maryam Ghavami, Zohreh Razaghi, Helda Tutunchi, Naimeh Mesri Alamdari · 2024 · Health Promotion Perspectives
30. A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis
    Daniel Adrian Fernández Félix, Gloriana Madrigal Loria, Sapna Sharma, Shorabh Sharma, Carlos E Arias Morales · 2022 · Cureus
31. Sodium-Glucose Cotransporter 2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: The Other Side of the Coin!
    Sangita Deepak Kamath, Umesh Kumar, Vikki Shrivastava · 2024 · Cureus
32. Rôle du glucagon dans la physiopathologie et le traitement du diabète
    Jean R Girard, Jean–François Gautier · 2016 · Médecine des Maladies Métaboliques
33. Euglycemic diabetic ketoacidosis in type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitors. A report on two cases
    Antonio Burgio, Maurizio Alletto, Salvatore Amico, Umberto Castiglione, Giovanni Fulco, Concetta Groppuso, Gianfranco Gruttadauria, Susanna Salvaggio, A Grande, Federico Vancheri · 2018 · Italian Journal of Medicine
34. Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip
    Marc T Zughaib, Kunjal Patel, Mariola Leka, Saif Affas · 2022 · Cureus
35. Implications and Economic Impact of Applying International Guidelines and Recommendations to the Management of High-Risk Group of Type 2 Diabetes Mellitus Patients in India
    Zeenat Fatima, Shubham Atal, Rajnish P. Joshi, Balakrishnan Sadasivam · 2022 · Cureus
36. Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis
    Gretchen M. Ray, Chelsea N. Rodriguez, Samantha Schulman, Preeyaporn Sarangarm, Michelle Bardack, Matthew Frederick Bouchonville · 2019 · Clinical Practice and Cases in Emergency Medicine
37. Expanding Treatment Options for Improving Health Outcomes in Type 1 Diabetes
    Satish K. Garg · 2017 · Diabetes Technology & Therapeutics
38. A case of perioperative euglycemic ketoacidosis in a patient without diabetes: are current guidelines enough?
    Shushmita Hoque, Rebecca Rick Longo, Paul Teague, Eugene S. Kim · 2025 · Perioperative Medicine
39. Euglycemic Diabetic Ketoacidosis and Its Prevention in Elective Surgical Patients Taking Sodium-Glucose Linked Transporter 2 Inhibitors: An International Perspective
    James H J Selbie, Shuhei Hiyama, Hemant G. Pandit · 2025 · Arthroplasty Today
40. Ketone Profiles in Community-Dwelling Adults with Type 1 Diabetes Using Continuous Ketone Monitoring
    Jennifer Ngan, Yee Wen Kong, Hanna C. Jones, Jenna Goad, Adamandia D. Kriketos, Adele Manzoney, Alicia Josephine Jenkins, Christopher James Nolan, Delaney Randle, Frank M. Gao et al. · 2026 · Diabetes Technology & Therapeutics
41. Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus – New Findings on SGLT2 Inhibitors
    Christian Karl Brinkmann · 2021 · Frontiers in Endocrinology
42. Empagliflozin: a wonder drug for the treatment of SIAD?
    Ploutarchos Tzoulis · 2024 · Frontiers in Endocrinology
43. Perioperative Considerations of Novel Antidiabetic Agents in Heart Failure Patients Undergoing Cardiac Surgery
    Ashley C. Wang, Savannah Bitzas, Dilsa Perez, Jonathon A. Schwartz, Saleem Zaidi, Jonathan Oster, Sergio Daniel Bergese · 2025 · Life
44. Revisiting the benefits vs risk profile of sodium-glucose co-transporter inhibitor use in type 1 diabetes Part A: Benefits of sodium-glucose co-transporter inhibitor use in type 1 diabetes
    Jennifer Ngan, David Norman O'Neal, Melissa H. Lee, Yee Wen Kong, Richard J. MacIsaac · 2025 · Diabetes Research and Clinical Practice
45. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
    Dragana Lovre, Wynn Htun, Carly Carrion, Vivian Andrew Fonseca · 2016 · Current Diabetes Reports
46. Dapagliflozin-Associated Diabetic Ketoacidosis
    Raja Chandra Chakinala, Anna P. Chang, Shantanu Solanki, Khwaja Fahad Haq, Ronald Cho · 2018 · American Journal of Therapeutics
47. An audit of the effect of SGLT2 inhibitor cessation in a pre‐admission clinic before and after Australian Diabetes Society guidelines
    Prishila Fookeerah, Henry Law, Farheen Ali, Katherine Chatten, Claire Kim, N. Wah Cheung · 2021 · Internal Medicine Journal
48. Preoperative optimization of diabetes
    Erin Stewart, Angela Roberts Selzer · 2021 · International Anesthesiology Clinics
49. Severe euglycemic diabetic ketoacidosis secondary to sodium-glucose co-transporter 2 inhibitor: case report and literature review
    Malak S. El Ess, Mohamed Elrishi · 2023 · Annals of Medicine and Surgery
50. Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure
    Kieran F. Docherty, Mark Colquhoun Petrie · 2021 · Heart
51. Sodium–glucose co‐transporter 2 inhibitors: a review of their use in older people with type 2 diabetes mellitus
    Angela Chen, Tilenka Thynne · 2016 · Journal of Pharmacy Practice and Research
52. Cetoacidosis diabética asociada a canagliflozina en diabetes mellitus tipo 2
    Silvia González Sanchidrián, Juan Ramón Gómez-Martino Arroyo, Pedro Jesús Labrador Gómez · 2016 · Medicina Clínica
53. Prevention of Hyperglycemia
    Lucy A. Ochola, Eric M. Guantai · 2021 · IntechOpen eBooks
54. Perioperative euglycemic DKA: The YIN and YANG of sodium-glucose cotransporter 2 inhibitors
    Shilpushp Jagannath Bhosale, Akash Golani, Malini Premkumar Joshi, Atul Prabhakar Kulkarni · 2025 · Journal of Anaesthesiology Clinical Pharmacology
55. Signal mining of adverse drug events related to hypovolemia caused by SGLT2 inhibitors based on FAERS database
    Huan Li, Ziwan Guan · 2025 · International Journal of Diabetes in Developing Countries
56. When Falls Reveal Acidosis: Unmasking Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor–Induced Euglycemic Diabetic Ketoacidosis
    Japleen Kaur, Angeli Dogra, Anna Haymov · 2025 · Cureus
57. The SGLT2 inhibitor checklist: a comprehensive review of perioperative and acute phase safety management
    Bin Deng, Wenhua Liu, Qingmin Chu · 2026 · Frontiers in Endocrinology
58. Safety and T1 reactivity for vasodilator stress ferumoxytol-enhanced cardiac magnetic resonance imaging
    Arutyun Pogosyan, Mary J. Keushkerian, Zhengyang Ming, Mostafa Mahmoudi, Myung S. Sim, Yuxin Li, J. Paul Finn, Kim‐Lien Nguyen · 2026 · Journal of Cardiovascular Magnetic Resonance
59. Use of Sodium-Glucose Cotransporter Inhibitors in Type 1 Diabetes: The Promise and the Perils
    Patricia R. Peter, Silvio E. Inzucchi · 2024 · Endocrine Practice
60. Cardiac catheterization in pulmonary arterial hypertension: Tips and tricks to enhance diagnosis and guide therapy
    Giulia Guglielmi, Kaushiga Krishnathasan, Andrew Harry Constantine, Konstantinos Dimopoulos · 2024 · International Journal of Cardiology Congenital Heart Disease
61. Overview of diabetes agents in cardiovascular disease: it takes an orchestra to play Tchaikovsky in symphony
    Wann Jia Loh · 2024 · Current Opinion in Endocrinology Diabetes and Obesity
62. Revisiting the benefits vs risk profile of sodium-glucose co-transporter inhibitor use in type 1 diabetes. Part B: Risks of sodium-glucose co-transporter inhibitor use in type 1 diabetes and ketoacidosis risk mitigation strategies
    Jennifer Ngan, David Norman O'Neal, Melissa H. Lee, Yee Wen Kong, Richard J. MacIsaac · 2025 · Diabetes Research and Clinical Practice
63. Advances in Cardiovascular Pharmacotherapy. IV. Sodium-Glucose Cotransporter Type 2 Inhibitors, Part 2: Mechanisms for Myocardial Protection, Adverse Effects, and Perioperative Implications
    Paul S. Pagel, Dustin Hang, Julie K. Freed, George J. Crystal · 2025 · Journal of Cardiothoracic and Vascular Anesthesia
64. Managing diabetic ketoacidosis in special conditions: Difficulties and dilemmas
    Sayantan Ray, Rajan Palui · 2025 · World Journal of Diabetes
65. Diabetic ketoacidosis associated to canagliflozin in type 2 diabetes
    Silvia González Sanchidrián, Juan Ramón Gómez-Martino Arroyo, Pedro Jesús Labrador Gómez · 2017 · Medicina Clínica (English Edition)
66. A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES
    M. Amosova, Valentin V. Fadeev · 2017 · Meditsinskiy sovet = Medical Council
67. Canagliflozin-associated diabetic ketoacidosis with lower-than-anticipated glucose levels
    Manjusha Agarwal · 2017 · Indian Journal of Critical Care Medicine
68. Role of Noninsulin Therapies in the Treatment of Type 1 Diabetes
    Sara E. Lingow, Sandra Drozdz Burke, Amie D. Brooks, Pat S. Rafferty · 2018 · Diabetes Spectrum
69. Sodium‐glucose co‐transporter 2 inhibitors in the peri‐operative period: A warning to all clinicians
    Anna Louise Waylen, Bernhard Riedel · 2019 · British Journal of Urology
70. Euglycemic Diabetic Ketoacidosis in the Surgical Patient
    David E. McCabe, Brian P. Strollo, George M. Fuhrman · 2020 · The American Surgeon
71. A case of sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis complicated by concurrent subacute thyroiditis
    Miyu Kinoshita, Koichiro Azuma, Tatsuo Yanagawa · 2022 · Journal of Clinical and Translational Endocrinology Case Reports
72. A Word-of-Caution Against Euglycaemic DKA!
    Rohan Magoon, Jes Jose · 2022 · Türk anesteziyoloji ve reanimasyon derneği dergisi
73. Canagliflozin in Type 1 Diabetes: A Case Series of Patient Outcomes in a Diabetes Clinic
    Tori Marie Roberts, June Felice Johnson, Amy Grace Vaughan · 2018 · Diabetes Spectrum
74. Zaviralci SGLT-2
    Mojca Lunder, Miodrag Janić, Mišo Šabović, Andrej Janež · 2018 · Slovenian Medical Journal
75. SGLT2 Inhibitors Therapy in Type 2 Diabetes Mellitus
    Maswood M. Ahmad, Imad Addin Brema, Mussa Almalki · 2019 · IntechOpen eBooks
76. Is It Justified to Have a Lower BMI Cutoff for Metabolic Surgery for Asians with Type 2 Diabetes?
    Satinath Mukhopadhyay, Deep Dutta · 2017 · Obesity Surgery
77. Reply
    Ammar W. Bhatti, Bhargav Makwana, Sumanth Khadke, Sourbha S. Dani, Sarju Ganatra · 2025 · JACC CardioOncology
78. An Approach to Diabetic Ketoacidosis in an Emergency Setting
    Dario Pitocco, Mauro A. S. Di Leo, Linda Tartaglione, Emanuele Gaetano Rizzo, Salvatore Caputo, Alessandro Rizzi, Alfredo Pontecorvi · 2020 · Reviews on Recent Clinical Trials
79. Euglycemic diabetic ketoacidosis associated with sodium–glucose cotransporter-2 inhibitors after surgery: A case report and review of literature
    Mei-An Tsai Pai, Tsai-Kun Wu, Shiaw-Wen Chien, Chang‐Hsu Chen, Yuan-Chuan Kuo, Hung-Ping Chen, Tien-Yu Tseng, Paik‐Seong Lim · 2023 · 童綜合醫學雜誌
80. Euglycemic Diabetic Ketoacidosis and Thyroid Storm Occurring During Dapagliflozin Treatment
    Ning Bai, Nan Wang, Ya Chen, Jian Zhu · 2025 · JCEM Case Reports
81. Diabetic Ketoacidosis Associated With Painless Thyroiditis in a Patient Treated With an SGLT2 Inhibitor
    Ryoichiro Aotani, Toshiaki Ohkuma, Ayaka Oshiro, Ken Okamura, Tetsuro Ago · 2025 · Case Reports in Endocrinology
82. Stereotypical diagnostic bias for alcohol‐induced ketoacidosis could lead to death: Normal blood sugar levels in SGLT2 blocker‐induced severe diabetic ketoacidosis
    Shun Kudo, Sho Endo, Yurina Nanahara, Takao KATAHIRA, Masayoshi Makio, Mikiko Yamauchi, Satoyuki Ogino, Akihiro Koreki, Takuto Ishida, Hiroyuki Uchida et al. · 2025 · Psychiatry and Clinical Neurosciences Reports
83. Perioperative screening and management of hyperglycemia: a joint position statement from the Brazilian Diabetes Society (SBD), the Brazilian Society of Anesthesiology (SBA) and the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO)
    E. C. Marino, Leandra Anália Freitas Negretto, Rogério Silicani Ribeiro, D. Momesso, A. Feitosa, Marcos T. K. Toyoshima, J. C. da Silva, S. Vencio, M. W. Lauria, J. D. de Sá et al. · 2026 · Diabetology & Metabolic Syndrome
84. Diabetic Ketoacidosis in a Patient with Type 1 Diabetes Mellitus Treated with Low Insulin in Combination with Empagliflozin
    José G. Jiménez-Montero, Christopher J. Mora-Aguilar, Chih Hao Chen-Ku · 2018 · AACE Clinical Case Reports
85. Diabetes, Prediabetes, and Metabolic Syndrome Among People Living with HIV
    Sowmya Chandra Reddy, William Bealle Moore, Papita Martina Rozario, Amy H. Warriner · 2019 · Springer eBooks
86. DIABETIC KETOACIDOSIS WITH LOWER-THAN-ANTICIPATED GLUCOSE LEVELS WITH SGLT-2 INHIBITOR CANAGLIFLOZIN: A CASE REPORT AND REVIEW OF THE LITERATURE.
    Ajay Budhwar, Parul Malhotra · 2020 · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH
87. SGLT-2i associated diabetic ketoacidosis in the setting of cardiogenic shock
    Alex Guzner, Ian A. Downs, Daniel Cruz, Casey Kaneshiro, Inês Donangelo · 2024 · BMJ Case Reports
88. SGLT ‐2 inhibitors and high‐dose acarbose as potential high‐risk combinations for ketosis and ketoacidosis in Asian patients with T2DM : A case series
    Wei Qiang, Fei Yang, Ling Liu, Ruiqing Dong, Yushi Sun, Ahona Mondal, Hui Guo · 2024 · Clinical Case Reports
89. Subcutaneous fast-acting insulin analogues ± long-acting insulin vs IV insulin infusion in DKA: updated meta-analysis of randomised trials
    Beng Leong Lim, Wei Feng Lee, Yan Ee Lynette Chung, Berlin Lee, Kee Vooi Loo · 2024 · Endocrine
90. Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on risk of diabetic eye complications
    Yi‐Hsuan Tsai, Nefertiti OjiNjideka Hemphill, Tobias Kurth · 2024 · Diabetologia
91. Recent advances in perioperative care of patients using new antihyperglycaemic drugs and devices dedicated to diabetes
    Rami El Ojaimi, Gaëlle Cheisson, Emmanuel Cosson, Carole Ichaï, Sophie Jacqueminet, Bogdan Catargi, Alexandre Ouattara, Igor Tauveron, Paul Elie Valensi, Dan Benhamou · 2024 · Anaesthesia Critical Care & Pain Medicine
92. Euglycemic Diabetic Ketoacidosis With Sepsis and Acute Kidney Injury in Critically Ill Patients: A Case Series
    Daichi Yomogida, Suguru Hasegawa, Shiori Mizuta, Shinjiro Horikawa, Yosinao Koshida · 2025 · Cureus
93. Diabetes mellitus tipo LADA y cetoacidosis: reflexiones a partir de un caso clínico
    Pilar Vich-Pérez, G. Mora Navarro, A. Espejo Gonzalez, M. López Fernandez de Santos · 2017 · Medicina de Familia SEMERGEN
94. Portuguese Society for the Study of Obesity / Recommendations on Nutritional and Pharmacological Management of Diabetes After Bariatric Surgery
    Marta Alves, Carla A. Pedrosa, Cláudia Freitas, Gustavo Rocha, Isabel Albuquerque, João Duarte, Luı́s Cardoso, Raquel Carvalho, Sandra Belo, Teresa Azevedo et al. · 2019 · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo
95. Diabetes
    Tiffany Chen · 2019 · Springer eBooks
96. Intravenous bolus-infusion versus sliding scale of insulin for intra-operative glycemic control in elective laparotomy surgeries
    Ghada Mohamed Samir, Mahmoud Abd El-Aziz Ghallab, Dalia Ibrahim · 2022 · Ain-Shams Journal of Anaesthesiology
97. Unexpected Acute Hyperglycemia Following Pre-Surgical Discontinuation of SGLT2 Inhibitors in a Type 1 Diabetic Patient
    Yuki Tsujimoto, Yosuke Nagai, Rimei Nishimura · 2023 · American Journal of Case Reports
98. “The Proof is in the Pudding”: Do SGLT2 Inhibitors Cause Diabetic Ketoacidosis?
    Elena I. Barengolts · 2017 · AACE Clinical Case Reports
99. The Safety and Efficacy of SGLT2 Inhibitors in Diabetes Mellitus Management
    Dominic Adam Worku · 2017 · ARC Journal of Diabetes and Endocrinology
100. Euglycemic diabetic ketoacidosis caused by canagliflozin: A rare case report
     SurinderPal Singh, Rupali Lahoria, Sachin Pandove, Deepak Bhasin, Harpal Singh, Rajit Jhingan · 2018 · Saudi Critical Care Journal